Keywords: Bristol-Myers Squibb, Nilojix, Organ transplant, Four-year data

Positive long-term results for Bristol-Myers Squibb's Nulojix in organ rejection

Article | 06 June 2012

Print This

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday presented the data at the 2012 American Transplant Congress in Boston, showing that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in